Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
123 articles about Altimmune, Inc.
-
Altimmune to Participate at Two Upcoming June 2023 Investor Conferences
5/31/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
5/11/2023
Altimmune, Inc. today announced financial results for the three months ended March 31, 2023, and provided a business update.
-
Altimmune to Participate at Two Upcoming Investor Conferences - May 8, 2023
5/8/2023
Altimmune, Inc. today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
5/4/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.
-
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
4/11/2023
Altimmune, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB).
-
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
3/27/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors.
-
Mayank Mamtani, managing director and group head of healthcare research at B. Riley Securities, told BioSpace he believes Altimmune's pemvidutide still shows promise despite safety concerns.
-
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
3/21/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes.
-
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
2/21/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.
-
Altimmune Appoints Raymond Jordt as Chief Business Officer
1/4/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023.
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
1/4/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023.
-
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
12/20/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.
-
Altimmune to Participate at Two Upcoming Investor Conferences - November 22, 2022
11/22/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022 Fireside chat at 10:55 am Eastern Time.
-
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
11/10/2022
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three and nine months ended September 30, 2022, and provided a business update.
-
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
11/3/2022
Altimmune, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.
-
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
10/28/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022.
-
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
9/28/2022
Altimmune, Inc. today announced the completion of first dosing of all subjects in its Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide 1 in subjects with obesity or overweight.
-
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
8/11/2022
Altimmune, Inc. today announced financial results for the three and six months ended June 30, 2022, and provided a business update.
-
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
8/4/2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update.
-
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.